Peter Bains appointed Additional Director of Biocon
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Company to open new headquarters in 2024
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Acquisition expands Merck’s growing hematology portfolio
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Subscribe To Our Newsletter & Stay Updated